Magenta Therapeutics

$10.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-0.87%) As of 4:40 PM UTC today

Why Robinhood?

You can buy or sell MGTA and other stocks, options, and ETFs commission-free!

About MGTA

Magenta Therapeutics, Inc. Common Stock, also called Magenta Therapeutics, is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA. The listed name for MGTA is Magenta Therapeutics, Inc. Common Stock.

CEO

Jason Gardner

Employees

Headquarters

Cambridge, Massachusetts

Founded

2015

Market Cap

452.30M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

517.68K

High Today

$10.32

Low Today

$9.51

Open Price

$9.90

Volume

258.74K

52 Week High

$12.63

52 Week Low

$5.76

MGTA Earnings

-$0.59

-$0.39

-$0.20

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 9, Pre-Market